About
Ophthalmics
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
600
By Phase
PHASE2: 2PHASE2/PHASE3: 1PHASE1: 1
By Status
COMPLETED: 2ACTIVE_NOT_RECRUITING: 1ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT04239625Lead Sponsor
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
PHASE2Active, not recruiting
200 participants
Started: Dec 20, 2019 · Completed: Dec 31, 2026
NCT03845582Lead Sponsor
Phase 2/3 Study of ALK-001 in Geographic Atrophy
PHASE2/PHASE3Completed
200 participants
Started: May 7, 2019 · Completed: Jun 30, 2024
NCT02402660Lead Sponsor
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
PHASE2Enrolling by invitation
160 participants
Started: Aug 31, 2015 · Completed: Nov 30, 2026
NCT02230228Lead Sponsor
Phase 1 Safety Study of ALK-001 in Healthy Volunteers
PHASE1Completed
40 participants
Started: Apr 30, 2014 · Completed: Feb 28, 2015
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...